Compare Etsy Inc (ETSY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Organon & Co. Common Stock — how do they compare? Etsy Inc trades at $82.96 (market cap $7.28B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Etsy Inc is far larger — about 2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Etsy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Organon & Co. Common Stock for 0 Days on average.
| ETSY | OGN | |
|---|---|---|
Market Cap | $7.28B | $3.62B |
Volume | 2,112,607 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $13.81 |
52-Week Low | $44.05 | $5.70 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $9.23B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY is trading at $82.93, up 7.8% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with positive moving averages and trades near analyst consensus targets. Recent news highlights AI integration initiatives and strategic partnerships, while financials show solid revenue growth but declining net margins from 11.19% in 2023 to 5.65% in 2025.
Outlook remains cautiously optimistic with 53% analyst buy ratings and $85.94 consensus target, though high P/B ratio and negative equity raise valuation concerns. Key risks include margin compression and competitive e-commerce pressures, while institutional accumulation and AI-driven personalization initiatives provide growth catalysts.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
